1
|
Nagata H, Sugimoto S, Hongo H, Hashimoto H, Sato Y, Kawabata T, Watanabe H, Inoue T, Usui K, Kurokawa C, Sasai K. Patient organ doses from megavoltage computed tomography delivery with a helical tomotherapy unit using a general treatment planning system. JOURNAL OF RADIATION RESEARCH 2019; 60:401-411. [PMID: 30929023 PMCID: PMC6530616 DOI: 10.1093/jrr/rrz005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/08/2018] [Revised: 10/19/2018] [Indexed: 06/09/2023]
Abstract
The purpose of this study was to quantify actual patient organ doses from megavoltage computed tomography (MVCT) using an MVCT beam model of a helical tomotherapy unit in a general treatment planning system (TPS). Dosimetric parameters (percentage depth dose, lateral beam profile, and longitudinal beam profile) of the MVCT beam were measured using Gafchromic EBT3 films (ISP Corporation, Wayne, NJ, USA) and used for beam modeling in a Pinnacle3 TPS (Philips, Amsterdam, Netherlands); this TPS is widely used with linear accelerators. The created beam model was adjusted and validated by assessing point doses in a cylindrical phantom in static and helical beam plans with fine, normal and coarse pitches. Maximum doses delivered to important organs from MVCT delivery for five clinical cases were calculated using the created beam model. The difference (average ± one standard deviation for all evaluation points) between calculated and measured doses was -0.69 ± 1.20% in the static beam plan. In the helical beam plan, the differences were 1.83 ± 2.65%, 1.35 ± 5.94% and -0.66 ± 8.48% for fine, normal and coarse pitches, respectively. The average maximum additional dose to important organs from MVCT in clinical cases was 0.82% of the prescribed dose. In conclusion, we investigated a method for quantifying patient organ dose from MVCT delivery on helical tomotherapy using an MVCT beam model in a general TPS. This technique enables estimation of the patient-specific organ dose from MVCT delivery, without the need for additional equipment.
Collapse
Affiliation(s)
- Hironori Nagata
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
- Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan
| | - Satoru Sugimoto
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| | - Hideyuki Hongo
- Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Kanagawa, Japan
| | - Harumitsu Hashimoto
- Department of Radiology, Shonan Fujisawa Tokusyukai Hospital, Fujisawa, Kanagawa, Japan
| | - Yuki Sato
- Technical Support Group, Radiation Therapy Technical Support Department, Hitachi, Ltd Healthcare Business Unit, Taito-ku, Tokyo, Japan
| | - Toru Kawabata
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| | - Hiroyuki Watanabe
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| | - Tatsuya Inoue
- Department of Radiology, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan
| | - Keisuke Usui
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| | - Chie Kurokawa
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| | - Keisuke Sasai
- Department of Radiation Oncology, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
2
|
Lyu Q, Yang C, Gao H, Xue Y, O'Connor D, Niu T, Sheng K. Technical Note: Iterative megavoltage CT (MVCT) reconstruction using block-matching 3D-transform (BM3D) regularization. Med Phys 2018; 45:2603-2610. [PMID: 29663467 DOI: 10.1002/mp.12916] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 03/05/2018] [Accepted: 04/04/2018] [Indexed: 01/04/2023] Open
Abstract
PURPOSE Megavoltage CT (MVCT) images are noisier than kilovoltage CT (KVCT) due to low detector efficiency to high-energy x rays. Conventional denoising methods compromise edge resolution and low-contrast object visibility. In this work, we incorporated block-matching 3D-transform shrinkage (BM3D) transformation into MVCT iterative reconstruction as nonlocal patch-wise regularization. METHODS The iterative reconstruction was achieved by adding to the existing least square data fidelity objective a regularization term, formulated as the L1 norm of the BM3D transformed image. A Fast Iterative Shrinkage-Thresholding Algorithm (FISTA) was adopted to accelerate CT reconstruction. The proposed method was compared against total variation (TV) regularization, BM3D postprocess method, and filtered back projection (FBP). RESULTS In the Catphan phantom study, BM3D regularization better enhances low-contrast objects compared with TV regularization and BM3D postprocess method at the same noise level. The spatial resolution using BM3D regularization is 2.79 and 2.55 times higher than that using the TV regularization at 50% of the modulation transfer function (MTF) magnitude, for the fully sampled reconstruction and down-sampled reconstruction, respectively. The BM3D regularization images show better bony details and low-contrast soft tissues, on the head and neck (H&N) and prostate patient images. CONCLUSIONS The proposed iterative BM3D regularization CT reconstruction method takes advantage of both the BM3D denoising capability and iterative reconstruction data fidelity consistency. This novel approach is superior to TV regularized iterative reconstruction or BM3D postprocess for improving noisy MVCT image quality.
Collapse
Affiliation(s)
- Qihui Lyu
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA
| | - Chunlin Yang
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Institute of Translational Medicine, Zhejiang University, Hangzhou, China
| | - Hao Gao
- Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
| | - Yi Xue
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Institute of Translational Medicine, Zhejiang University, Hangzhou, China
| | - Daniel O'Connor
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA
| | - Tianye Niu
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Institute of Translational Medicine, Zhejiang University, Hangzhou, China
| | - Ke Sheng
- Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
3
|
Klawikowski S, Tai A, Ates O, Ahunbay E, Li XA. A fast 4D IMRT/VMAT planning method based on segment aperture morphing. Med Phys 2018; 45:1594-1602. [DOI: 10.1002/mp.12778] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 12/28/2017] [Accepted: 01/02/2018] [Indexed: 12/25/2022] Open
Affiliation(s)
- Slade Klawikowski
- Department of Radiation Oncology; The Medical College of Wisconsin; Milwaukee WI USA
| | - An Tai
- Department of Radiation Oncology; The Medical College of Wisconsin; Milwaukee WI USA
| | - Ozgur Ates
- Department of Radiation Oncology; The Medical College of Wisconsin; Milwaukee WI USA
| | - Ergun Ahunbay
- Department of Radiation Oncology; The Medical College of Wisconsin; Milwaukee WI USA
| | - X. Allen Li
- Department of Radiation Oncology; The Medical College of Wisconsin; Milwaukee WI USA
| |
Collapse
|
4
|
Paix A, Antoni D, Waissi W, Ledoux MP, Bilger K, Fornecker L, Noel G. Total body irradiation in allogeneic bone marrow transplantation conditioning regimens: A review. Crit Rev Oncol Hematol 2018; 123:138-148. [PMID: 29482775 DOI: 10.1016/j.critrevonc.2018.01.011] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 09/28/2017] [Accepted: 01/24/2018] [Indexed: 12/30/2022] Open
Abstract
Hematologic malignancies may require, at one point during their treatment, allogeneic bone marrow transplantation. Total body irradiation combined with chemotherapy or radiomimetic used in allogeneic bone marrow transplantation is known to be very toxic. Total body irradiation (TBI) induces immunosuppression to prevent the rejection of donor marrow. TBI is also used to eradicate malignant cells and is in sanctuary organs that are not reached by chemotherapy drugs. TBI has evolved since its introduction in the late fifties, but acute and late toxicities remain. Helical tomotherapy, which is widely used for some solid tumors, is a path for the improvement of outcomes and toxicities in TBI because of its sparing capacities. In this article, we first review the practical aspects of TBI with patient positioning, radiobiological considerations and total dose and fractionation prescriptions. Second, we review the use of intensity modulated radiation therapy in bone marrow transplantation with a focus on helical tomotherapy TBI, helical tomotherapy total marrow irradiation (TMI) and total marrow and lymphoid irradiation (TMLI) and their dosimetric and clinical outcomes. Finally, we review the perspective of dose escalation and the extension to older patients and patients with comorbidity who do not benefit from a standard bone marrow transplantation conditioning regimen.
Collapse
Affiliation(s)
- Adrien Paix
- Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France
| | - Delphine Antoni
- Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France; Radiobiology Laboratory, EA3430, Strasbourg University, 3 rue de la Porte de l'hôpital, 67000, Strasbourg, France
| | - Waisse Waissi
- Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France; Radiobiology Laboratory, EA3430, Strasbourg University, 3 rue de la Porte de l'hôpital, 67000, Strasbourg, France
| | - Marie-Pierre Ledoux
- Hematology Department, CHU Hautepierre, 1, rue Molière, 67000, Strasbourg, France
| | - Karin Bilger
- Hematology Department, CHU Hautepierre, 1, rue Molière, 67000, Strasbourg, France
| | - Luc Fornecker
- Hematology Department, CHU Hautepierre, 1, rue Molière, 67000, Strasbourg, France
| | - Georges Noel
- Radiation Oncology Department, Centre Paul Strauss 3 rue de la Porte de l'hôpital, 67065, Strasbourg Cedex, France; Radiobiology Laboratory, EA3430, Strasbourg University, 3 rue de la Porte de l'hôpital, 67000, Strasbourg, France.
| |
Collapse
|
5
|
Zhu F, Wu W, Zhu F, Wang Y, Wang Y, Xia T. Influence of computed tomography contrast agent on radiotherapy dose calculation for pancreatic carcinoma: A dosimetric study based on tomotherapy and volumetric-modulated arc therapy techniques. Med Dosim 2017; 42:317-325. [PMID: 28818321 DOI: 10.1016/j.meddos.2017.07.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 04/18/2017] [Accepted: 07/03/2017] [Indexed: 11/30/2022]
Abstract
The main purpose of our investigation was to quantify the dosimetric influence of intravenous contrast agent for pancreatic cancer radiotherapy treatment. This study focused on complex modulated irradiation techniques of tomotherapy (TOMO) and volumetric-modulated arc therapy (VMAT) to investigate if novel conformal treatment methods could reduce the influence of contrast agent. In our study, patients with pancreatic cancer were enrolled to have 2 computed tomography (CT) scans in the same position without and with intravenous contrast agent for treatment planning. Then tumors and organ at risks were countered on contrast-enhanced CT (CECT) images. Each patient's CECT was assigned a TOMO plan and a VMAT plan. Then these plans were copied onto the non-CECT image and dose distribution was calculated with the same algorithm and structure sets. Finally, the dose distribution and the dose difference were analyzed for the target volume and organs at risk between the 2 sets of images. The statistic dosimetric result showed that for both TOMO and VMAT, no significant dose difference between CECT and non-CECT-based plan was observed. Dose difference was clinically negligible because the average relative percentage dose difference was 1% ± 1% for target volume, except a blurring effect at the higher dose region of the target volume. It implied that intravenous contrast agent will not affect dose calculation for pancreatic cancer radiotherapy significantly. Also the dose deviation based on TOMO showed no statistical difference compared with that on VMAT. For both superposition/conversation algorithm used by TOMO and Monte Carlo algorithm used by VMAT, the dosimetric difference was nonsignificant. A full analysis demonstrated a negligible dose difference of less than 1% between CECT-based plan and non-CECT-based plan. Therefore, contrast-enhanced CT image can be used directly for dose calculation of TOMO and VMAT plans for pancreatic cancer. It is unnecessary to scan twice then make a fusion of CECT and non-CECT, which would result to additional unnecessary radiation dose to patient and decrease work efficiency.
Collapse
Affiliation(s)
- Feng Zhu
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China
| | - Weizhang Wu
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China
| | - Fuhai Zhu
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China
| | - Yong Wang
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China
| | - Yingjie Wang
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China
| | - Tingyi Xia
- Department of Radiation Oncology, PLA General Airforce Hospital, 30 Fucheng Street, Beijing 100142, China.
| |
Collapse
|
6
|
Nagai A, Shibamoto Y, Yoshida M, Inoda K, Kikuchi Y. Intensity-modulated radiotherapy using two static ports of tomotherapy for breast cancer after conservative surgery: dosimetric comparison with other treatment methods and 3-year clinical results. JOURNAL OF RADIATION RESEARCH 2017; 58:529-536. [PMID: 28339844 PMCID: PMC5570131 DOI: 10.1093/jrr/rrw132] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 10/23/2016] [Indexed: 06/06/2023]
Abstract
This study investigated the differences in dose-volume parameters for the breast and normal tissues during TomoDirectTM (TD) intensity-modulated radiation therapy (IMRT), TD-3D conformal radiotherapy (3DCRT) and 3DCRT plans, all using two beams, and analyzed treatment outcomes of two-beam TD-IMRT for breast cancer after breast-conserving surgery. Between August 2011 and January 2015, 152 patients were treated using two-beam TD-IMRT with 50 Gy/25 fractions. Among them, 20 patients with left-sided breast cancer were randomly chosen, and two-beam TD-IMRT, TD-3DCRT and 3DCRT plans were created for each patient. The homogeneity and conformity indices and various dose-volume parameters for the planning target volume and OARs were evaluated. Clinical outcomes were evaluated at 3 years. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. TD-IMRT and TD-3DCRT showed better whole-breast coverage than 3DCRT (P < 0.001). Most of the mean values of dosimetric endpoints for OARs were better in TD-IMRT than in TD-3DCRT and 3DCRT. Overall survival rates were 97.7% and local control rates were 99.1% at 3 years. Regional control and distant metastasis control rates at 3 years were 98.6% and 96.8%, respectively. Twenty-four of the 152 patients had Grade 2 or higher acute radiation dermatitis. Four patients (4/146 = 2.7%) had Grade 2 radiation pneumonitis. There were no late adverse events of Grade 2 or higher. Two-beam TD-IMRT appeared to yield better dose distribution for whole-breast external-beam radiation therapy than TD-3DCRT and two-beam 3DCRT. The treatment appeared to provide low skin toxicity and acceptable tumor control.
Collapse
Affiliation(s)
- Aiko Nagai
- Radiation Therapy Center, Fukui Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
| | - Yuta Shibamoto
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
| | - Masanori Yoshida
- Radiation Therapy Center, Fukui Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan
| | - Koji Inoda
- Department of Radiological Technology, Fukui Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan
| | - Yuzo Kikuchi
- Radiation Therapy Center, Fukui Saiseikai Hospital, 7-1, Funabashi, Wadanaka-cho, Fukui 918-8503, Japan
| |
Collapse
|
7
|
Magome T, Haga A, Takahashi Y, Nakagawa K, Dusenbery KE, Hui SK. Fast Megavoltage Computed Tomography: A Rapid Imaging Method for Total Body or Marrow Irradiation in Helical Tomotherapy. Int J Radiat Oncol Biol Phys 2016; 96:688-95. [PMID: 27681766 DOI: 10.1016/j.ijrobp.2016.06.2458] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Revised: 06/22/2016] [Accepted: 06/26/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE Megavoltage computed tomographic (MVCT) imaging has been widely used for the 3-dimensional (3-D) setup of patients treated with helical tomotherapy (HT). One drawback of MVCT is its very long imaging time, the result of slow couch speeds of approximately 1 mm/s, which can be difficult for the patient to tolerate. We sought to develop an MVCT imaging method allowing faster couch speeds and to assess its accuracy for image guidance for HT. METHODS AND MATERIALS Three cadavers were scanned 4 times with couch speeds of 1, 2, 3, and 4 mm/s. The resulting MVCT images were reconstructed using an iterative reconstruction (IR) algorithm with a penalty term of total variation and with a conventional filtered back projection (FBP) algorithm. The MVCT images were registered with kilovoltage CT images, and the registration errors from the 2 reconstruction algorithms were compared. This fast MVCT imaging was tested in 3 cases of total marrow irradiation as a clinical trial. RESULTS The 3-D registration errors of the MVCT images reconstructed with the IR algorithm were smaller than the errors of images reconstructed with the FBP algorithm at fast couch speeds (2, 3, 4 mm/s). The scan time and imaging dose at a speed of 4 mm/s were reduced to 30% of those from a conventional coarse mode scan. For the patient imaging, faster MVCT (3 mm/s couch speed) scanning reduced the imaging time and still generated images useful for anatomic registration. CONCLUSIONS Fast MVCT with the IR algorithm is clinically feasible for large 3-D target localization, which may reduce the overall time for the treatment procedure. This technique may also be useful for calculating daily dose distributions or organ motion analyses in HT treatment over a wide area. Automated integration of this imaging is at least needed to further assess its clinical benefits.
Collapse
Affiliation(s)
- Taiki Magome
- Department of Radiological Sciences, Faculty of Health Sciences, Komazawa University, Tokyo, Japan; Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
| | - Akihiro Haga
- Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan
| | - Yutaka Takahashi
- Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Department of Radiation Oncology, Osaka University, Osaka, Japan
| | - Keiichi Nakagawa
- Department of Radiology, The University of Tokyo Hospital, Tokyo, Japan
| | - Kathryn E Dusenbery
- Department of Therapeutic Radiology, University of Minnesota, Minneapolis, Minnesota
| | - Susanta K Hui
- Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Department of Therapeutic Radiology, University of Minnesota, Minneapolis, Minnesota; Department of Radiation Oncology and Beckman Research Institute, City of Hope, Duarte, California.
| |
Collapse
|
8
|
Peñagarícano JA, Shi C, Ratanatharathorn V. Evaluation of Integral Dose in Cranio-spinal Axis (CSA) Irradiation with Conventional and Helical Delivery. Technol Cancer Res Treat 2016; 4:683-9. [PMID: 16292889 DOI: 10.1177/153303460500400613] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
In cranio-spinal axis (CSA) irradiation, patients are usually treated in the prone position with junctions between cranial and spinal fields. Collimator angle and pedestal rotations are introduced to obtain coplanar alignment of the matched junction. Furthermore, daily moving junctions are commonly used to feather out the junctional dose as additional safe-guards to avoid radiation myelopathy. Helical tomotherapy integrates linear accelerator and CT technology capable of delivering CSA treatment without geometric matches or feathering of junctions. The patient is treated with helical beams in the supine position. Since CSA is used mainly in the pediatric population, the potential increase in integral dose to structures or the whole body from linac- or tomotherapy-based IMRT raises concerns of increased rates of secondary malignancies. In this study, we will present an integral dose comparison between conventional CSA (3D) and helical delivery to the CSA (TOMO) utilizing the Tomotherapy Hi-ART system for three pediatric patients. Integral dose was calculated for organ at risk (OAR), two targets (PTV-BRAIN and PTV-SPINE), entire planning CT data set and to the healthy tissue (entire CT-DATA SET minus the PTV). Overall integral dose was 8% higher in the TOMO plans for Patients #1 and #3, but 2% lower in Patient #2. DVH analysis shows that TOMO plans give lower doses to larger volumes and higher doses to smaller volumes of tissue in all three cases. The advantages of the TOMO plans are minimization of matched junctions and better sparing of most OARs. With increased computational and memory power in the tomotherapy planning station, the excess integral dose to the healthy tissue can be re-distributed within the patient and in turn the total integral dose can be same or lower than in conventional delivery. The impact of a small increase in overall integral dose and the associated risks of secondary malignancies are unknown. Long-term follow-up is needed to answer this question.
Collapse
Affiliation(s)
- José A Peñagarícano
- Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, 72205, USA.
| | | | | |
Collapse
|
9
|
Novel applications of TomoTherapy in the treatment of metastases. Radiography (Lond) 2015. [DOI: 10.1016/j.radi.2014.06.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
10
|
Nguyen NP, Vock J, Vinh-Hung V, Khan R, Slane B, Sroka T, Jang S, Dias V, Vo RA, Karlsson U, Chi A. Feasibility of Tomotherapy for Postoperative Irradiation of Lower Extremity Sarcomas. TUMORI JOURNAL 2014. [DOI: 10.1177/1636.17914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Nam P Nguyen
- Department of Radiation Oncology, Howard University, Washington, DC, USA
| | - Jacqueline Vock
- Department of Radiation Oncology, Lindenhofspital, Bern, Switzerland
| | - Vincent Vinh-Hung
- Department of Radiation Oncology, University Hospital of Martinique, Fort de France, France
| | | | - Benjamin Slane
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Thomas Sroka
- Department of Radiation Oncology, Dartmouth College, Hanover, NH, USA
| | - Siyoung Jang
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Vigil Dias
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Richard A Vo
- Department of Pediatrics, University of Virginia, Charlottesville, VA, USA
| | - Ulf Karlsson
- Department of Radiation Oncology, Marshfield Clinic, Marshfield, WI, USA
| | - Alexander Chi
- Department of Radiation Oncology, University of West Virginia, Morgantown, WV, USA
| |
Collapse
|
11
|
Murai T, Murata R, Manabe Y, Sugie C, Tamura T, Ito H, Miyoshi Y, Shibamoto Y. Intensity modulated stereotactic body radiation therapy for single or multiple vertebral metastases with spinal cord compression. Pract Radiat Oncol 2014; 4:e231-7. [PMID: 25407874 DOI: 10.1016/j.prro.2014.02.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 02/17/2014] [Accepted: 02/17/2014] [Indexed: 12/25/2022]
Abstract
PURPOSE The purpose of this study was to evaluate the efficacy and toxicity of intensity modulated radiation therapy with simultaneous integrated boost (SIB-IMRT) for single or multiple vertebral metastases (VM) with spinal cord compression using tomotherapy. METHODS AND MATERIALS Thirty patients with 40 VM were treated with SIB-IMRT as initial radiation therapy. Either 40 Gy in 8 fractions or 48 Gy in 16 fractions was prescribed depending on the Katagiri prognostic index. The radiation doses to the spinal cord and other risk organs were reduced to tolerance levels using intensity modulation. One to 4 lesions in consecutive vertebrae were treated in 1 course of SIB-IMRT. Radiologic and physical examinations were performed at 1-3 month intervals after SIB-IMRT. The Barthel index (BI) and numerical rating scale (NRS) were used to evaluate activities of daily living (ADL) and pain status, respectively. RESULTS The median follow-up period was 8 months. The NRS significantly dropped at 1 month after SIB-IMRT (P < .0001) and the effect continued for over 2 months. No significant BI decrease was observed at 2 months after SIB-IMRT (P = .7). The 1-year local control rate was 84% (95% confidence interval, 70%-100%). No grade≥2 neurologic toxicity resulting from SIB-IMRT was observed. CONCLUSIONS SIB-IMRT could be successfully applied to VM with spinal cord compression in up to 4 consecutive vertebrae. Good ADL preservation and pain control were achieved with acceptable toxicity.
Collapse
Affiliation(s)
- Taro Murai
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Department of Radiation Oncology, Yokohama CyberKnife Center, Yokohama, Japan.
| | - Rumi Murata
- Department of Radiation Oncology, JA Suzuka General Hospital, Suzuka, Japan
| | - Yoshihiko Manabe
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Chikao Sugie
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Takeshi Tamura
- Department of Radiation Oncology, JA Suzuka General Hospital, Suzuka, Japan
| | - Hiroya Ito
- Department of Radiation Oncology, JA Suzuka General Hospital, Suzuka, Japan
| | - Yoshihito Miyoshi
- Department of Radiation Oncology, JA Suzuka General Hospital, Suzuka, Japan
| | - Yuta Shibamoto
- Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| |
Collapse
|
12
|
Piotrowski T, Czajka E, Bak B, Kazmierska J, Skorska M, Ryczkowski A, Adamczyk M, Jodda A. Tomotherapy: implications on daily workload and scheduling patients based on three years' institutional experience. Technol Cancer Res Treat 2013; 13:233-42. [PMID: 24066951 DOI: 10.7785/tcrt.2012.500374] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Helical tomotherapy (HT) was introduced at the Greater Poland Cancer Centre (GPCC) in April 2009. Retrospective analysis included data from the treatments performed for the first 656 patients treated with HT between May 2009 and May 2012 at the GPCC. In order to evaluate the implications on daily workload and scheduling of patients, stepwise regression and time analysis for each component of the overall treatment time, such as positioning, imaging, registration, and irradiation were performed. A detailed analysis included: (1) learning curves and optimized time needed for positioning and registration; (2) relation between irradiation time and parameters used for plan creation; and (3) average time of daily imaging. The irradiation component has the highest influence on the overall treatment time (R = 0.911). The lowest influence was observed for the imaging (R = 0.670). The learning curve for positioning was 7 months while the reduction of the average daily time needed for registration was observed even after two years. The irradiation time strongly depends on the planning parameters. Changing the pitch from 0.215 to 0.287 for pelvic cancer cases decreased the average daily beam-on time per patient by about 2 minutes. Similar changes for head and neck reduced this time by 1.3 minutes. The limitation in the usage of 1 cm field width only for complex cases, lower than 10 cm in the cranio-caudal direction, reduced the beam-on time per patient by 2 minutes. The average overall treatment time decreased from 21.5 minutes per patient in the first year of the HT usage to 13.8 minutes per patient in current practice. Our current practice shows that for a group of patients including mainly those with pelvis and head and neck cancers, the HT treatment takes approximately 15 minutes per patient allowing 40 patients to be treated within 10 hours.
Collapse
Affiliation(s)
- T Piotrowski
- Department of Medical Physics, University of Medical Sciences, Poznan, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Feasibility of image-guided radiotherapy for elderly patients with locally advanced rectal cancer. PLoS One 2013; 8:e71250. [PMID: 23967173 PMCID: PMC3742779 DOI: 10.1371/journal.pone.0071250] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Accepted: 06/26/2013] [Indexed: 01/03/2023] Open
Abstract
Purpose The study aims to assess the tolerance of elderly patients (70 years or older) with locally advanced rectal cancers to image-guided radiotherapy (IGRT). A retrospective review of 13 elderly patients with locally advanced rectal cancer who underwent preoperative chemoradiation using IGRT was performed. Grade 3–4 acute toxicities, survival, and long-term complications were compared to 17 younger patients (<70 years) with the same disease stage. Results Grade 3–4 hematologic toxicities occurred in 7.6% and 0% (p = 0.4) and gastrointestinal toxicities, and, in 15.2% and 5% (p = 0.5), of elderly and younger patients, respectively. Surgery was aborted in three patients, two in the elderly group and one in the younger group. One patient in the elderly group died after surgery from cardiac arrhythmia. After a median follow-up of 34 months, five patients had died, two in the elderly and three in the younger group. The 3-year survival was 90.9% and 87.5% (p = 0.7) for the elderly and younger group respectively. Two patients in the younger group developed ischemic colitis and fecal incontinence. There was no statistically significant difference in acute and late toxicities as well as survival between the two groups. Conclusions and Clinical Relevance Elderly patients with locally advanced rectal cancers may tolerate preoperative chemoradiation with IGRT as well as younger patients. Further prospective studies should be performed to investigate the potential of IGRT for possible cure in elderly patients with locally advanced rectal cancer.
Collapse
|
14
|
Dhanesar S, Darko J, Joshi CP, Kerr A, John Schreiner L. Cobalt-60 tomotherapy: Clinical treatment planning and phantom dose delivery studies. Med Phys 2013; 40:081710. [DOI: 10.1118/1.4812417] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
15
|
Van Gestel D, Verellen D, Van De Voorde L, de Ost B, De Kerf G, Vanderveken O, Van Laer C, Van den Weyngaert D, Vermorken JB, Gregoire V. The potential of helical tomotherapy in the treatment of head and neck cancer. Oncologist 2013; 18:697-706. [PMID: 23723331 PMCID: PMC4063397 DOI: 10.1634/theoncologist.2012-0424] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2012] [Accepted: 03/27/2013] [Indexed: 12/28/2022] Open
Abstract
A decade after its first introduction into the clinic, little is known about the clinical impact of helical tomotherapy (HT) on head and neck cancer (HNC) treatment. Therefore, we analyzed the basics of this technique and reviewed the literature regarding HT's potential benefit in HNC. The past two decades have been characterized by a huge technological evolution in photon beam radiotherapy (RT). In HNC, static beam intensity-modulated radiotherapy (IMRT) has shown superiority over three-dimensional conformal RT in terms of xerostomia and is considered the standard of care. However, the next-generation IMRT, the rotational IMRT, has been introduced into the clinic without any evidence of superiority over static beam IMRT other than being substantially faster. Of these rotational techniques, HT is the first system especially developed for IMRT in combination with image-guided RT. HT is particularly promising for the treatment of HNC because its sharp dose gradients maximally spare the many radiosensitive organs at risk nearby. In addition, HT's integrated computed tomography scan assures a very precise dose administration and allows for some adaptive RT. Because HT is specifically developed for IMRT in combination with (integrated) image-guidance, it allows for precise dose distribution ("dose painting"), patient setup, and dose delivery. As such, it is an excellent tool for difficult HNC irradiation. The literature on the clinical results of HT in HNC all show excellent short-term (≤2 years) results with acceptable toxicity profiles. However, properly designed trials are still warranted to further substantiate these results.
Collapse
Affiliation(s)
- Dirk Van Gestel
- Department of Radiotherapy, University Radiotherapy Antwerp, Antwerp, Belgium.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kramkimel N, Dendale R, Bolle S, Zefkili S, Fourquet A, Kirova Y. Management of advanced non-melanoma skin cancers using helical tomotherapy. J Eur Acad Dermatol Venereol 2013; 28:641-50. [DOI: 10.1111/jdv.12152] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2012] [Accepted: 03/06/2013] [Indexed: 11/29/2022]
Affiliation(s)
- N. Kramkimel
- Department of Radiation Oncology; Curie Institute; Paris France
- Department of Dermatology; Cochin Hospital; Paris France
| | - R. Dendale
- Department of Radiation Oncology; Curie Institute; Paris France
| | - S. Bolle
- Department of Radiation Oncology; Curie Institute; Paris France
| | - S. Zefkili
- Department of Radiation Oncology; Curie Institute; Paris France
| | - A. Fourquet
- Department of Radiation Oncology; Curie Institute; Paris France
| | - Y.M. Kirova
- Department of Radiation Oncology; Curie Institute; Paris France
| |
Collapse
|
17
|
Nguyen NP, Ceizyk M, Vinh-Hung V, Sroka T, Jang S, Khan R, Locke A, Albala G, Truong C, Godinez J, Vo R, Smith-Raymond L. Feasibility of tomotherapy to reduce cochlea radiation dose in patients with locally advanced nasopharyngeal cancer. TUMORI JOURNAL 2012; 98:709-14. [DOI: 10.1177/030089161209800606] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background To evaluate the effectiveness of tomotherapy-based image-guided radiotherapy (IGRT) on the radiation dose to the cochlea in patients with nasopharyngeal cancer. Methods and study design A retrospective review of five patients undergoing concurrent chemoradiation with tomotherapy for locally advanced nasopharyngeal cancer was performed. Results The mean dose to the right and left cochlea was 25 Gy and 35.3 Gy respectively, while the dose to the gross tumor ranged from 70 to 75 Gy. All patients had excellent clinical response to the treatment at a median follow-up of five months. Conclusions IGRT for head and neck cancer delivered by tomotherapy can significantly decrease the radiation dose to the cochlea without sacrificing target volume coverage.
Collapse
Affiliation(s)
- Nam P Nguyen
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Misty Ceizyk
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Vincent Vinh-Hung
- Department of Radiation Oncology, University Hospitals of Geneva, Geneva, Switzerland
| | - Thomas Sroka
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Siyoung Jang
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Rihan Khan
- Department of Radiology, University of Arizona, Tucson, AZ, USA
| | - Angela Locke
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Gabby Albala
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Christina Truong
- Department of Radiation Oncology, University of Arizona, Tucson, AZ, USA
| | - Juan Godinez
- Florida Radiation Oncology Group, Palatka, FL, USA
| | - Richard Vo
- University of Galveston Medical School, Galveston, TX, USA
| | | |
Collapse
|
18
|
Quality assurance of TomoDirect treatment plans using I'mRT MatriXX. Biomed Imaging Interv J 2012; 8:e14. [PMID: 22970070 PMCID: PMC3432260 DOI: 10.2349/biij.8.2.e14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2011] [Revised: 02/02/2012] [Accepted: 02/05/2012] [Indexed: 11/17/2022] Open
Abstract
Purpose: To evaluate the performance of 2D-array I’mRT MatriXX for dose verification of TomoDirect treatment plans. Methods: In this study, a 2D-array ion chamber device – the I’mRT MatriXX and Multicube Phantom from IBA – was used for dose verification of different TomoDirect plans. Pre-treatment megavoltage computed tomography (MVCT) was performed on the phantom setup for position correction. After the irradiation of treatment plans on the I’mRT MatriXX and Multicube Phantom, the measured doses of coronal planes were compared with those from the planning calculations for verification. The results were evaluated by comparing the absolute dose difference in the high dose region as well as the gamma analysis of the 2D-dose distributions on the coronal plane. The comparison was then repeated with the measured dose corrected for angular dependence of the MatriXX. Results: When angular dependence is taken into account, the passing rate of gamma analysis is over 90% for all measurements using the MatriXX. If there is no angular dependence correction, the passing rate of gamma analysis worsens for treatment plans with dose contribution from the rear. The passing rate can be as low as 53.55% in extreme cases, i.e. where all doses in the treatment plan are delivered from the rear. Conclusion: It is important to correct the measured dose for angular dependence when verifying TomoDirect treatment plans using the MatriXX. If left uncorrected, a large dose discrepancy may be introduced to the verification results.
Collapse
|
19
|
Jung JH, Cho KH, Kim YH, Moon SK, Min CK, Kim WC, Kim ES, Chang AR, Kim TH, Yoon JW, Suh TS, Huh HD. Effect of jaw size in megavoltage CT on image quality and dose. Med Phys 2012; 39:4976-83. [PMID: 22894422 DOI: 10.1118/1.4736951] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Recently, the jaw size for the TomoTherapy Hi-Art II(®) (TomoTherapy Inc., Madison, WI) was reduced from 4 mm (J4) to 1 mm (J1) to improve the longitudinal (IEC-Y) resolution in megavoltage computed tomography (MVCT) images. This study evaluated the effect of jaw size on the image quality and dose, as well as the dose delivered to the lens of the eye, which is a highly radiosensitive tissue. METHODS MVCT image quality (image noise, uniformity, contrast linearity, high-contrast resolution, and full width at half-maximum) and multiple scan average dose (MSAD) were measured at different jaw sizes. A head phantom and photoluminescence glass dosimeters (PLDs) were used to measure the exposed lens dose (cGy). Different MVCT scan modes (pitch = 1, 2, and 3) and scan lengths (108 mm, 156 mm, and 204 mm) were applied in the MSAD and PLDs measurements. RESULTS The change in jaw size from J4 to J1 produced no change or only a slight improvement in image noise, uniformity, contrast linearity, and high-contrast resolution. However, the full-width at half-maximum reduced from approximately 7.2 at J4 to 4.5 mm at J1, which represents an enhancement in the longitudinal resolution. The MSAD at the center point changed from approximately 0.69-2.32 cGy (peripheral: 0.83-2.49 cGy) at J4 to 0.85-2.81 cGy (peripheral: 1.05-2.86 cGy) at J1. The measured lens dose increased from 0.92-3.36 cGy at J4 to 1.06-3.91 cGy at J1. CONCLUSIONS The change in jaw size improved longitudinal resolution. The MVCT imaging dose of approximately 3.86 cGy, 1.92 cGy, and 1.22 cGy was delivered at a pitch of 1, 2, and 3, respectively, per fraction in the head and neck treatment plans. Therefore, allowance for an approximately 15% increase in lens dose over that with J4 should be provided with J1.
Collapse
Affiliation(s)
- Jae Hong Jung
- Department of Radiation Oncology, College of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 1174, Korea
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Nguyen NP, Vos P, Vinh-Hung V, Ceizyk M, Smith-Raymond L, Stevie M, Slane B, Chi A, Desai A, Krafft SP, Jang S, Hamilton R, Karlsson U, Abraham D. Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer. BMC Cancer 2012; 12:175. [PMID: 22578076 PMCID: PMC3411401 DOI: 10.1186/1471-2407-12-175] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2011] [Accepted: 05/11/2012] [Indexed: 12/02/2022] Open
Abstract
Background To evaluate the feasibility of image-guided radiotherapy based on helical Tomotherapy to spare the contralateral parotid gland in head and neck cancer patients with unilateral or no neck node metastases. Methods A retrospective review of 52 patients undergoing radiotherapy for head and neck cancers with image guidance based on daily megavoltage CT imaging with helical tomotherapy was performed. Results Mean contralateral parotid dose and the volume of the contralateral parotid receiving 40 Gy or more were compared between radiotherapy plans with significant constraint (SC) of less than 20 Gy on parotid dose (23 patients) and the conventional constraint (CC) of 26 Gy (29 patients). All patients had PTV coverage of at least 95% to the contralateral elective neck nodes. Mean contralateral parotid dose was, respectively, 14.1 Gy and 24.7 Gy for the SC and CC plans (p < 0.0001). The volume of contralateral parotid receiving 40 Gy or more was respectively 5.3% and 18.2% (p < 0.0001) Conclusion Tomotherapy for head and neck cancer minimized radiotherapy dose to the contralateral parotid gland in patients undergoing elective node irradiation without sacrificing target coverage.
Collapse
Affiliation(s)
- Nam P Nguyen
- Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases. Radiat Oncol 2012; 7:42. [PMID: 22436144 PMCID: PMC3341183 DOI: 10.1186/1748-717x-7-42] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2012] [Accepted: 03/21/2012] [Indexed: 11/26/2022] Open
Abstract
Background Our research group has previously published a dosimetric planning study that demonstrated that a 60 Gy/10 fractions intralesional boost with whole-brain radiotherapy (WBRT) to 30 Gy/10 fractions was biologically equivalent with a stereotactic radiosurgery (SRS) boost of 18 Gy/1 fraction with 30 Gy/10 fractions WBRT. Helical tomotherapy (HT) was found to be dosimetrically equivalent to SRS in terms of target coverage and superior to SRS in terms of normal tissue tolerance. A phase I trial has been now completed at our institution with a total of 60 enrolled patients and 48 evaluable patients. The phase II dose has been determined to be the final phase I cohort dose of 60 Gy/10 fractions. Methods/Design The objective of this clinical trial is to subject the final phase I cohort dose to a phase II assessment of the endpoints of overall survival, intracranial control (ICC) and intralesional control (ILC). We hypothesize HT would be considered unsuitable for further study if the median OS for patients treated with the HT SIB technique is degraded by 2 months, or the intracranial progression-free rates (ICC and ILC) are inferior by 10% or greater compared to the expected results with treatment by whole brain plus SRS as defined by the RTOG randomized trial. A sample size of 93 patients was calculated based on these parameters as well as the statistical assumptions of alpha = 0.025 and beta = 0.1 due to multiple statistical testing. Secondary assessments of toxicity, health-related quality-of-life, cognitive changes, and tumor response are also integrated into this research protocol. Discussion To summarize, the purpose of this phase II trial is to assess this non-invasive alternative to SRS in terms of central nervous system (CNS) control when compared to SRS historical controls. A follow-up phase III trial may be required depending on the results of this trial in order to definitively assess non-inferiority/superiority of this approach. Ultimately, the purpose of this line of research is to provide patients with metastatic disease to the brain a shorter course, dose intense, non-invasive radiation treatment with equivalent or improved CNS control/survival and health-related quality-of-life/toxicity profile when compared to SRS radiotherapy. Trial registration Clinicaltrials.gov - NCT01543542.
Collapse
|
22
|
Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol 2011; 84:967-96. [PMID: 22011829 DOI: 10.1259/bjr/22373346] [Citation(s) in RCA: 431] [Impact Index Per Article: 33.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Volumetric modulated arc therapy (VMAT) is a novel radiation technique, which can achieve highly conformal dose distributions with improved target volume coverage and sparing of normal tissues compared with conventional radiotherapy techniques. VMAT also has the potential to offer additional advantages, such as reduced treatment delivery time compared with conventional static field intensity modulated radiotherapy (IMRT). The clinical worldwide use of VMAT is increasing significantly. Currently the majority of published data on VMAT are limited to planning and feasibility studies, although there is emerging clinical outcome data in several tumour sites. This article aims to discuss the current use of VMAT techniques in practice and review the available data from planning and clinical outcome studies in various tumour sites including prostate, pelvis (lower gastrointestinal, gynaecological), head and neck, thoracic, central nervous system, breast and other tumour sites.
Collapse
Affiliation(s)
- M Teoh
- Department of Oncology, St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.
| | | | | | | | | |
Collapse
|
23
|
Chatterjee S, Willis N, Locks SM, Mott JH, Kelly CG. Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity-modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas. Br J Radiol 2011; 84:1083-90. [PMID: 22101580 PMCID: PMC3473826 DOI: 10.1259/bjr/53812025] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2010] [Revised: 08/20/2010] [Accepted: 08/24/2010] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVES The usual radical radiotherapy treatment prescribed for head and neck squamous cell carcinoma (HNSCC) is 70 Gy (in 2 Gy per fraction equivalent) administered to the high-risk target volume (TV). This can be planned using either a forward-planned photon-electron junction technique (2P) or a single-phase (1P) forward-planned technique developed in-house. Alternatively, intensity-modulated radiotherapy (IMRT) techniques, including helical tomotherapy (HT), allow image-guided inversely planned treatments. This study was designed to compare these three planning techniques with regards to TV coverage and the dose received by organs at risk. METHODS We compared the dose-volume histograms and conformity indices (CI) of the three planning processes in five patients with HNSCC. The tumour control probability (TCP), normal tissue complication probability (NTCP) and uncomplicated tumour control probability (UCP) were calculated for each of the 15 plans. In addition, we explored the radiobiological rationality of a dose-escalation strategy. RESULTS The CI for the high-risk clinical TV (CTV1) in the 5 patients were 0.78, 0.76, 0.82, 0.72 and 0.81 when HT was used; 0.58, 0.56, 0.47, 0.35 and 0.60 for the single-phase forward-planned technique and 0.46, 0.36, 0.29, 0.22 and 0.49 for the two-phase technique. The TCP for CTV1 with HT were 79.2%, 85.2%, 81.1%, 83.0% and 53.0%; for single-phase forward-planned technique, 76.5%, 86.9%, 73.4%, 81.8% and 31.8% and for the two-phase technique, 38.2%, 86.2%, 42.7%, 0.0% and 3.4%. Dose escalation using HT confirmed the radiobiological advantage in terms of TCP. CONCLUSION TCP for the single-phase plans was comparable to that of HT plans, whereas that for the two-phase technique was lower. Centres that cannot provide IMRT for the radical treatment of all patients could implement the single-phase technique as standard to attain comparable TCP. However, IMRT produced better UCP, thereby enabling the exploration of dose escalation.
Collapse
Affiliation(s)
- S Chatterjee
- Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.
| | | | | | | | | |
Collapse
|
24
|
Nguyen NP, Krafft SP, Vinh-Hung V, Vos P, Almeida F, Jang S, Ceizyk M, Desai A, Davis R, Hamilton R, Modarresifar H, Abraham D, Smith-Raymond L. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol 2011; 101:438-42. [PMID: 21908064 DOI: 10.1016/j.radonc.2011.07.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2010] [Revised: 06/16/2011] [Accepted: 07/24/2011] [Indexed: 11/17/2022]
Abstract
PURPOSE To compare the effectiveness of tomotherapy and three-dimensional (3D) conformal radiotherapy to spare normal critical structures (spinal cord, lungs, and ventricles) from excessive radiation in patients with distal esophageal cancers. MATERIALS AND METHODS A retrospective dosimetric study of nine patients who had advanced gastro-esophageal (GE) junction cancer (7) or thoracic esophageal cancer (2) extending into the distal esophagus. Two plans were created for each of the patients. A three-dimensional plan was constructed with either three (anteroposterior, right posterior oblique, and left posterior oblique) or four (right anterior oblique, left anterior oblique, right posterior oblique, and left posterior oblique) fields. The second plan was for tomotherapy. Doses were 45 Gy to the PTV with an integrated boost of 5 Gy for tomotherapy. RESULTS Mean lung dose was respectively 7.4 and 11.8 Gy (p=0.004) for tomotherapy and 3D plans. Corresponding values were 12.4 and 18.3 Gy (p=0.006) for cardiac ventricles. Maximum spinal cord dose was respectively 31.3 and 37.4 Gy (p < 0.007) for tomotherapy and 3D plans. Homogeneity index was two for both groups. CONCLUSIONS Compared to 3D conformal radiotherapy, tomotherapy decreased significantly the amount of normal tissue irradiated and may reduce treatment toxicity for possible dose escalation in future prospective studies.
Collapse
Affiliation(s)
- Nam P Nguyen
- Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724-5081, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Rong Y, Welsh JS. Dosimetric and clinical review of helical tomotherapy. Expert Rev Anticancer Ther 2011; 11:309-20. [PMID: 21342048 DOI: 10.1586/era.10.175] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
As a modality for delivering rotational therapy, helical tomotherapy offers dosimetric advantages by combining a continuously rotating gantry with a binary multileaf collimator. Helical tomotherapy, embodied in the TomoTherapy(®) Hi-Art II(®) system, delivers intensity-modulated fan beams in a helical pattern using binary multileaf collimator leaves while the couch is translated through the gantry. Helical tomotherapy offers the possibility of treating a variety of cases--from simple to complex--with improved target conformality and sensitive structure sparing compared with 3D or conventional static field IMRT plans, thereby allowing biologically effective dose escalation. For precise irradiation and possible treatment adaptation, the fully integrated on-board image-guidance system provides online volumetric images of patient anatomy using 3.5-MV x-ray beams and the xenon computed tomography detector. Several review articles were published before the year 2007 but emphasized the technical aspects of helical tomotherapy. In this article, we review very recent papers and focus on the dosimetric and clinical aspects of helical tomotherapy.
Collapse
Affiliation(s)
- Yi Rong
- Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI, USA.
| | | |
Collapse
|
26
|
Abstract
PURPOSE To describe early clinical results of tomotherapy treatment in patients with breast cancer and complex treatment volumes. METHODS AND MATERIALS Ten patients were treated with tomotherapy between January 2009 and March 2010. Treatment planning objectives were to cover at least 95% of the planning target volume with the 95% isodose; to have a minimum dose of 90% and a maximum dose of 105%. All treatments included daily CT/megavoltage image guidance. Acute toxicity was recorded weekly. RESULTS Six patients were treated because constraints were not accomplished for heart, lung or contralateral breast in a previous three-dimensional conformal plan; two for preexisting cardiac or pulmonary disease, and two more for bilateral breast irradiation. Treatment volumes included the whole breast in the majority of patients, as well as the supraclavicular and the internal mammary chain nodes when indicated. Most patients were older than 50 years, and had an early breast cancer, with positive oestrogen receptors, negative HER2 expression and a poorly differentiated, infiltrating ductal carcinoma. The majority of patients had received neoadjuvant chemotherapy associated to breast-conserving surgery and adjuvant hormonotherapy. Median homogeneity index was 1.09; median coverage index was 0.81. Median V20Gy and V10Gy for ipsilateral lung was 20% and 37.1% respectively. Median V25 and V35 for heart was 15% and 4% respectively. Median dose for contralateral breast was 7 Gy. Skin acute toxicity was grade 1 in 41.7% and grade 2 in 58.3%. CONCLUSION Tomotherapy is a technique capable of delivering a well tolerated treatment with high homogeneity and coverage indexes and high capabilities for sparing the organs at risk in patients with anatomically complex breast cancer, bilateral breast cancer, indication for internal mammary chain node irradiation, cardiac toxicity derived from chemotherapy, or preexisting cardiac or pulmonary disease. Further studies are required to evaluate local control and late toxicity.
Collapse
|
27
|
|
28
|
Sylvestre A, Mahé MA, Lisbona A, Zefkili S, Savignoni A, Bonnette P, Barthes FLP, Paris E, Perigaud C, Yassa M, Giraud P. Mesothelioma at era of helical tomotherapy: results of two institutions in combining chemotherapy, surgery and radiotherapy. Lung Cancer 2011; 74:486-91. [PMID: 21663996 DOI: 10.1016/j.lungcan.2011.05.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2011] [Revised: 04/28/2011] [Accepted: 05/04/2011] [Indexed: 10/18/2022]
Abstract
PURPOSE There is a scarce clinical experience about adjuvant helical tomotherapy (HT) in patients affected by malignant pleural mesothelioma (MPM) even though it appears as a useful technique to treat complex volume as the pleural cavity, and seems to have better dose distribution than the "classic" intensity modulated radiotherapy (IMRT). METHODS AND MATERIALS Twenty-four patients received adjuvant radiotherapy (RT) by HT from August 1st, 2007 to December 1st, 2009 at Curie Institute (Paris) and René Gauducheau Cancer Center (Nantes). Thirteen patients had neoadjuvant chemotherapy. Extrapleural pleuropneumonectomy (EPP) was done in 23 patients. Median dose to PTV was 50Gy [48.7-55.9Gy] (2Gy/fraction). Acute and long term toxicities, disease free survival (DFS), overall survival (OS) and relapses are presented. RESULTS Average follow up after RT was 7 months. The disease was staged mostly as T2-T3, N1-N2. Nineteen patients had epithelial type histology. Most patients tolerated radiotherapy with grade 1-2 side effects: redness of the skin, light cough or dyspnea, fatigue, nausea and odynophagia, mild increase of the post-operative thoracic pain. Grade 3 pneumonitis was suspected in 2 patients. Two grade 5 pneumonitis were also suspected. Eleven patients had a follow up of more than 6 months and no long term side effects related with HT were noted. At 24 months, 51.8% of patients were free of disease. Thirty percent of patients relapsed, with 2 patients presenting local relapses. Two patients died from recurrence. CONCLUSION With limited follow up, HT has comparable toxicity to those observed with traditional IMRT. Higher radiation dose and good coverage results in excellent local control.
Collapse
Affiliation(s)
- Alma Sylvestre
- Department of Radiation Oncology, European Georges-Pompidou Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
[Value of tomotherapy in malignant pleural mesothelioma: first clinical results]. Rev Mal Respir 2011; 28:609-17. [PMID: 21645831 DOI: 10.1016/j.rmr.2011.03.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Accepted: 10/14/2010] [Indexed: 12/29/2022]
Abstract
INTRODUCTION There is little clinical data about the place of helicoidal tomotherapy (HT) in the treatment of malignant pleural mesothelioma (MPM). This new form of intensity modulated radiotherapy (IMRT) has great theoretical advantages in large and complex volumes when compared to "traditional" forms of radiotherapy. PATIENTS AND METHODS Fourteen patients diagnosed with MPM received adjuvant radiotherapy by HT. The patients were treated at the Curie Institute and the René Gauducheau Centre, starting in August 12007. All patients had a complete initial staging, an extrapleural pneumonectomy (EPP), and a minimum follow-up of six months. The median dose prescribed to the surgical cavity was 50 Gy (48-54 Gy) in 2 Gy (1.80-2.07) fractions. High dose regions received concomitant 57 Gy (54-69 Gy) in 2.16 Gy (2.00-2.30 Gy) fractions. RESULTS Median follow-up was 12.6 months after ending HT. Seven patients received neoadjuvant chemotherapy (cisplatin or carboplatin, and pemetrexed). Eight patients were staged pT3 and five were staged pN1-2. HT was well tolerated. Two patients had suspected G5 radiation pneumonitis within 6 months of ending HT. Of the 12 patients who survived treatment, six relapsed (in average 5.1 months after HT): distant. Four relapses were distant; two relapses were both local and distant. Three patients died after their initial relapse. After initial diagnosis, the median survival was 18.4 months. A learning curve was observed in the optimization of the dosimetric parameters. CONCLUSION Helicoidal tomotherapy is a reliable, quite well tolerated, and efficient way of treating MPM patients after an EPP.
Collapse
|
30
|
Nguyen NP, Smith-Raymond L, Vinh-Hung V, Sloan D, Davis R, Vos P, Abraham D, Stevie M, Krafft SP, Ly BH, Ries T, Karlsson U, Ceizyk M. Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head and neck cancer. Oral Oncol 2011; 47:414-9. [DOI: 10.1016/j.oraloncology.2011.03.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2010] [Revised: 03/10/2011] [Accepted: 03/10/2011] [Indexed: 11/27/2022]
|
31
|
Chatterjee S, Mott JH, Smyth G, Dickson S, Dobrowsky W, Kelly CG. Clinical challenges in the implementation of a tomotherapy service for head and neck cancer patients in a regional UK radiotherapy centre. Br J Radiol 2011; 84:358-66. [PMID: 21159810 PMCID: PMC3473475 DOI: 10.1259/bjr/19586137] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2010] [Revised: 02/16/2010] [Accepted: 02/16/2010] [Indexed: 11/05/2022] Open
Abstract
OBJECTIVE Intensity-modulated radiotherapy (IMRT) is increasingly being used to treat head and neck cancer cases. METHODS We discuss the clinical challenges associated with the setting up of an image guided intensity modulated radiotherapy service for a subset of head and neck cancer patients, using a recently commissioned helical tomotherapy (HT) Hi Art (Tomotherapy Inc, WI) machine in this article. We also discuss the clinical aspects of the tomotherapy planning process, treatment and image guidance experiences for the first 10 head and neck cancer cases. The concepts of geographical miss along with tomotherapy-specific effects, including that of field width and megavoltage CT (MVCT) imaging strategy, have been highlighted using the first 10 head and neck cases treated. RESULTS There is a need for effective streamlining of all aspects of the service to ensure compliance with cancer waiting time targets. We discuss how patient toxicity audits are crucial to guide refinement of the newly set-up planning dose constraints. CONCLUSION This article highlights the important clinical issues one must consider when setting up a head and neck IMRT, image-guided radiotherapy service. It shares some of the clinical challenges we have faced during the setting up of a tomotherapy service. Implementation of a clinical tomotherapy service requires a multidisciplinary team approach and relies heavily on good team working and effective communication between different staff groups.
Collapse
Affiliation(s)
- S Chatterjee
- Northern Centre for Cancer Care, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, UK.
| | | | | | | | | | | |
Collapse
|
32
|
Kirova YM, Chargari C. Applications of new irradiation modalities in patients with lymphoma: Promises and uncertainties. World J Radiol 2011; 3:66-9. [PMID: 21512653 PMCID: PMC3080052 DOI: 10.4329/wjr.v3.i3.66] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2011] [Revised: 03/02/2011] [Accepted: 03/09/2011] [Indexed: 02/06/2023] Open
Abstract
New highly conformal irradiation modalities have emerged for treatment of Hodgkin lymphoma. Helical tomotherapy offers both intensity-modulated irradiation and accurate patient positioning and was shown to significantly decrease radiation doses to the critical organs. Here we review some of the most promising applications of helical tomotherapy in Hodgkin disease. By decreasing doses to the heart or the breast, helical tomotherapy might decrease the risk of long-term cardiac toxicity or secondary breast cancers, which are major concerns in patients receiving chest radiotherapy. Other strategies, such as debulking radiotherapy prior to stem cell transplantation or total lymphoid irradiation may be clinically relevant. However, helical tomotherapy may also increase the volume of tissues that receive lower doses, which has been implicated in the carcinogenesis process. Prospective assessments of these new irradiation modalities of helical tomotherapy are required to confirm the potential benefits of highly conformal therapies applied to hematological malignancies.
Collapse
|
33
|
Schiappacasse L, Cendales R, Sallabanda K, Schnitman F, Samblas J. Preliminary results of helical tomotherapy in patients with complex-shaped meningiomas close to the optic pathway. Med Dosim 2011; 36:416-22. [PMID: 21397487 DOI: 10.1016/j.meddos.2010.10.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2010] [Revised: 10/17/2010] [Accepted: 10/21/2010] [Indexed: 10/18/2022]
Abstract
Meningiomas are the most common benign intracranial tumor. Meningiomas close to the optic pathway represent a treatment challenge both for surgery and radiotherapy. The aim of this article is to describe early results of helical tomotherapy treatment in complex-shaped meningiomas close to the optic pathway. Twenty-eight patients were consecutively treated. All patients were immobilized with a thermoplastic head mask and planned with the aid of a magnetic resonance imaging-computed tomography fusion. All treatments included daily image guidance. Pretreatment symptoms and acute toxicity were recorded. Median age was 57.5 years, and 92.8% patients had Eastern Cooperative Oncology Group performance status scale ≤1. The most common localizations were the sella turcica, followed by the cavernous sinus and the sphenoid. The most common symptoms were derived from cranial nerve deficits. Tomotherapy was administered as primary treatment in 35.7% of patients, as an adjuvant treatment in 32.4%, and as a rescue treatment after postsurgical progression in 32.1% patients. Most patients were either inoperable or Simpson IV. Total dose varied between 5000 and 5400 cGy; fractionation varied between 180 and 200 cGy. Median dose to the planning target volume was 51.7 Gy (range, 50.2-55.9 Gy). Median coverage index was 0.89 (range, 0.18-0.97). Median homogeneity index was 1.05 (range, 1-1.12). Acute transient toxicity was grade 1 and included headache in 35.7% patients, ocular pain/dryness in 28.5%, and radiation dermatitis in 25%. Thus far, with a maximal follow-up of 3 years, no late effects have been seen and all patients have a radiological stabilization of the disease. Helical tomotherapy offered a safe and effective therapeutic alternative for patients with inoperable or subtotally resected complex-shaped meningiomas close to the optic pathway. Acceptable coverage and homogeneity indexes were achieved with appropriate values for maximal doses delivered to the eyes, lenses, and chiasm, despite the proximity of the tumor to these structures.
Collapse
Affiliation(s)
- Luis Schiappacasse
- Tomotherapy Department, Clinica La Milagrosa, IMO Group (Instituto Madrileno de Oncologia), Madrid, Spain.
| | | | | | | | | |
Collapse
|
34
|
Elith C, Dempsey SE, Findlay N, Warren-Forward HM. An Introduction to the Intensity-modulated Radiation Therapy (IMRT) Techniques, Tomotherapy, and VMAT. J Med Imaging Radiat Sci 2011; 42:37-43. [DOI: 10.1016/j.jmir.2010.11.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Accepted: 11/10/2010] [Indexed: 12/31/2022]
|
35
|
Chang CC, Chi KH, Kao SJ, Hsu PS, Tsang YW, Chang HJ, Yeh YW, Hsieh YS, Jiang JS. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. Lung Cancer 2011; 73:189-94. [PMID: 21247653 DOI: 10.1016/j.lungcan.2010.12.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2010] [Revised: 11/30/2010] [Accepted: 12/09/2010] [Indexed: 02/05/2023]
Abstract
BACKGROUND Upfront tyrosine kinase inhibitor (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. We hypothesized that early integration of radiotherapy during TKI treatment would decrease the chance of drug resistance and prolong progression-free survival (PFS). METHODS This study included 25 patients with stage IIIb or IV non-squamous cell, non-small cell lung cancer (NSqCLC) who responded to upfront TKI treatment. Multi-target radiotherapy was administered during the TKI treatment course. Tomotherapy comprising a hypofractionated schedule with a dose of 40-50 Gy in 16-20 fractions was used for individual metastatic lesions. RESULTS The patients' median follow-up duration was 30 months (range, 9-62 months). Of the 23 patients who had stage IV disease, 9 had oligometastases (≤5 gross target volumes) and 14 were in the more advanced stages of the disease. Twelve patients received more than 1 cycle of radiotherapy (median, 3; range, 2-6) with TKI being the only systemic treatment before they were salvaged with chemotherapy. The overall response rate after radiotherapy was 84.0%, and the median PFS was 16 months. The 3-year overall survival rate was 62.5% (95% confidence interval [CI], 39.1-85.8%). Toxicities were generally tolerated but it is necessary to prevent radiation-induced pneumonitis. CONCLUSION We showed that combined first-line TKI therapy and early multi-target radiotherapy are very effective in selected patients that respond to TKI, when the status of mutations in the epidermal growth factor receptor (EGFR) are not known before the treatment. Our data may aid expansion of the effectiveness of TKI treatment through radiotherapy in Asian patients with stage IV NSqCLC.
Collapse
Affiliation(s)
- Chih-Chia Chang
- Department of Radiation Therapy and Oncology, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Dusenbery KE, Gerbi BJ. Total Body Irradiation Conditioning Regimens in Stem Cell Transplantation. MEDICAL RADIOLOGY 2011. [DOI: 10.1007/174_2011_281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
|
37
|
He W, Vazquez LA, Shi C, Papanikolaou N. Sensitivity study to evaluate the dosimetric impact of off-axis ratio profiles misalignment on TomoTherapy second dose validation. Technol Cancer Res Treat 2010; 9:515-22. [PMID: 20815423 DOI: 10.1177/153303461000900510] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Accurate dose planning and delivery are very important in the intensity modulated radiation therapy. For helical TomoTherapy dose validation, a TomoTherapy second check software, called MU-Tomo, has been developed using archived patient documents, initial coordinates and planned dose of the point of calculation, and common dosimetric functions. Based on this software, sensitivity studies on 50 patient cases have been evaluated to show the impact of off-axis ratio profile misalignment on point dose calculation. Off-axis ratio is defined as the dose profile normalized to its maximum dose value. Sensitivity studies were done for three scenarios: oscillating the fluctuation regions of two off-axis profiles, shifting the profiles, and rotating the profiles. The result of the oscillation trial is linear along the change of longitudinal off-axis ratio (OARy), while oscillating the lateral off-axis ratio (OARx) has little influence on the dose calculation. For shifting, the variation in the percentage difference from the non-shifting value is about 15 times larger in OARy modification than in OARx modification. Rotating OARx by +/- 6' gave less than 1.5% +/- 0.20% difference compared to the non-rotating value. Rotating OARy by +/- 1' changes the result more than 5% +/- 2.69%. Therefore, for helical TomoTherapy dose validation, commissioned OARy profiles are more sensitive than OARx to oscillation, shifting and rotating. As a result, different tolerances for OARx and OARy may be required for annual quality assurance.
Collapse
Affiliation(s)
- Weihong He
- 7979 Wurzbach Rd Ste 240, Cancer Therapy and Research Center, Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, TX 78229, USA
| | | | | | | |
Collapse
|
38
|
Chatterjee S, Lee D, Kent N, Wintle T, Mott JH, Kelly CG, Branson AN. Managing supraclavicular disease from breast cancer with brachial plexus-sparing techniques using helical tomotherapy. Clin Oncol (R Coll Radiol) 2010; 23:101-7. [PMID: 21055911 DOI: 10.1016/j.clon.2010.09.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2010] [Revised: 08/09/2010] [Accepted: 09/22/2010] [Indexed: 12/25/2022]
Abstract
AIMS Managing supraclavicular fossa (SCF) disease in patients with breast cancer can be challenging, with brachial plexopathy recognised as a complication of high-dose radiotherapy to the SCF. Local control of SCF disease is an important end point. Intensity-modulated radiotherapy (IMRT) techniques provide a steep dose gradient and improve the therapeutic index, making it possible to escalate dose to planning target volumes (PTVs), while reducing the dose to organs at risk (OAR). We explored image-guided IMRT techniques using helical tomotherapy to dose escalate SCF lymph nodes with a view to restrict the dose to the brachial plexus. MATERIALS AND METHODS Three cases with SCF nodal disease in varying clinical stages of breast cancer were planned and treated using helical tomotherapy-IMRT to assess the feasibility and safety of radiotherapy dose escalation to improve the chances of local control in SCF while restricting the dose to the brachial plexus. Consultant clinical oncologists were asked to define the PTVs and OARs as per agreed inhouse policy. The brachial plexus was outlined as a separate OAR in all three cases. In case 1 the left breast and SCF were treated with adjuvant radiotherapy (40 Gy in 15 fractions) with a sequential boost (10 Gy in five fractions) to the SCF PTV. In case 2, local recurrence was salvaged using a simultaneous integrated boost to the gross tumour plus a 3 mm margin to 63 Gy and 54 Gy to the entire SCF. Case 3 was to control nodal disease with re-irradiation of the SCF to a median dose of 44 Gy, while maintaining a low dose to the brachial plexus. Inverse planning constraints (helical tomotherapy) were applied to the PTV and OARs with the brachial plexus allowed a maximum biologically effective dose (BED) of 120 Gy. RESULTS It was possible to treat the SCF to a higher dose using helical tomotherapy-IMRT. The treatment was successful in controlling disease in the SCF. No patients reported symptoms suggestive of brachial plexopathy. CONCLUSION Sequential or simultaneous integrated boost to the SCF was safe and feasible. This is the first publication of dose escalation to the SCF when treating breast cancer with brachial plexus-sparing IMRT techniques. The feasibility of such techniques warrants a multicentre phase II study of dose escalation with IMRT to improve local control in isolated SCF disease.
Collapse
Affiliation(s)
- S Chatterjee
- Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.
| | | | | | | | | | | | | |
Collapse
|
39
|
Nguyen NP, Ceizyk M, Almeida F, Chi A, Betz M, Modarresifar H, Sroka T, Cohen D, Jang S, Abraham D, Stevie M, Smith-Raymond L, Krafft S, Vinh-Hung V. Effectiveness of Image-Guided Radiotherapy for Locally Advanced Rectal Cancer. Ann Surg Oncol 2010; 18:380-5. [DOI: 10.1245/s10434-010-1329-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2010] [Indexed: 11/18/2022]
|
40
|
Lawrence JA, Forrest LJ, Turek MM, Miller PE, Mackie TR, Jaradat HA, Vail DM, Dubielzig RR, Chappell R, Mehta MP. Proof of principle of ocular sparing in dogs with sinonasal tumors treated with intensity-modulated radiation therapy. Vet Radiol Ultrasound 2010; 51:561-570. [PMID: 20973393 PMCID: PMC2966034 DOI: 10.1111/j.1740-8261.2010.01695.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2024] Open
Abstract
Intensity-modulated radiation therapy (IMRT) allows optimization of radiation dose delivery to complex tumor volumes with rapid dose drop-off to surrounding normal tissues. A prospective study was performed to evaluate the concept of conformal avoidance using IMRT in canine sinonasal cancer. The potential of IMRT to improve clinical outcome with respect to acute and late ocular toxicity was evaluated. Thirty-one dogs with sinonasal cancer were treated definitively with IMRT using helical tomotherapy and/or dynamic multileaf collimator (DMLC) delivery. Ocular toxicity was evaluated prospectively and compared with a comparable group of historical controls treated with conventional two-dimensional radiotherapy (2D-RT) techniques. Treatment plans were devised for each dog using helical tomotherapy and DMLC that achieved the target dose to the planning treatment volume and limited critical normal tissues to the prescribed dose-volume constraints. Overall acute and late toxicities were limited and minor, detectable by an experienced observer. This was in contrast to the profound ocular morbidity observed in the historical control group treated with 2D-RT. Overall median survival for IMRT-treated and 2D-treated dogs was 420 and 411 days, respectively. Compared with conventional techniques, IMRT reduced dose delivered to eyes and resulted in bilateral ocular sparing in the dogs reported herein. These data provide proof-of-principle that conformal avoidance radiotherapy can be delivered through high conformity IMRT, resulting in decreased normal tissue toxicity as compared with historical controls treated with 2D-RT.
Collapse
Affiliation(s)
- Jessica A. Lawrence
- The School of Veterinary Medicine Department of Medical Sciences, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Lisa J. Forrest
- The School of Veterinary Medicine Department of Surgical Sciences, and University of Wisconsin-Madison, Madison, WI, 53706, USA
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Michelle M. Turek
- The School of Veterinary Medicine Department of Surgical Sciences, and University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Paul E. Miller
- The School of Veterinary Medicine Department of Surgical Sciences, and University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - T. Rockwell Mackie
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53706, USA
- TomoTherapy Inc., Madison, WI 53717
| | - Hazim A. Jaradat
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - David M. Vail
- The School of Veterinary Medicine Department of Medical Sciences, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Richard R. Dubielzig
- The School of Veterinary Medicine Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Richard Chappell
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, 53706, USA
| | - Minesh P. Mehta
- Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI, 53706, USA
- Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, 53706, USA
- TomoTherapy Inc., Madison, WI 53717
| |
Collapse
|
41
|
Rodrigues G, Yartsev S, Yaremko B, Perera F, Dar AR, Hammond A, Lock M, Yu E, Ash R, Caudrelier JM, Khuntia D, Bailey L, Bauman G. Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases. Int J Radiat Oncol Biol Phys 2010; 80:1128-33. [PMID: 20675078 DOI: 10.1016/j.ijrobp.2010.03.047] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2010] [Revised: 03/30/2010] [Accepted: 03/31/2010] [Indexed: 12/22/2022]
Abstract
PURPOSE Stereotactic radiosurgery is an alternative to surgical resection for selected intracranial lesions. Integrated image-guided intensity-modulated-capable radiotherapy platforms such as helical tomotherapy (HT) could potentially replace traditional radiosurgery apparatus. The present study's objective was to determine the maximally tolerated dose of a simultaneous in-field boost integrated with whole brain radiotherapy for palliative treatment of patients with one to three brain metastases using HT. METHODS AND MATERIALS The inclusion/exclusion criteria and endpoints were consistent with the Radiation Therapy Oncology Group 9508 radiosurgery trial. The cohorts were constructed with a 3 + 3 design; however, additional patients were enrolled in the lower dose tolerable cohorts during the toxicity assessment periods. Whole brain radiotherapy (30 Gy in 10 fractions) was delivered with a 5-30-Gy (total lesion dose of 35-60 Gy in 10 fractions) simultaneous in-field boost delivered to the brain metastases. The maximally tolerated dose was determined by the frequency of neurologic Grade 3-5 National Cancer Institute Common Toxicity Criteria, version 3.0, dose-limiting toxicity events within each Phase I cohort. RESULTS A total of 48 patients received treatment in the 35-Gy (n = 3), 40-Gy (n = 16), 50-Gy (n = 15), 55-Gy (n = 8), and 60-Gy (n = 6) cohorts. No patients experienced dose-limiting toxicity events in any of the trial cohorts. The 3-month RECIST assessments available for 32 of the 48 patients demonstrated a complete response in 2, a partial response in 16, stable disease in 6, and progressive disease in 8 patients. CONCLUSION The delivery of 60 Gy in 10 fractions to one to three brain metastases synchronously with 30 Gy whole brain radiotherapy was achieved without dose-limiting central nervous system toxicity as assessed 3 months after treatment. This approach is being tested in a Phase II efficacy trial.
Collapse
Affiliation(s)
- George Rodrigues
- Department of Oncology, University of Western Ontario and London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Jursinic PA, Sharma R, Reuter J. MapCHECK used for rotational IMRT measurements: Step-and-shoot, Tomotherapy, RapidArc. Med Phys 2010; 37:2837-46. [DOI: 10.1118/1.3431994] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
43
|
Duchateau M, Tournel K, Verellen D, Van de Vondel I, Reynders T, Linthout N, Gevaert T, de Coninck P, Depuydt T, Storme G. The effect of tomotherapy imaging beam output instabilities on dose calculation. Phys Med Biol 2010; 55:N329-36. [DOI: 10.1088/0031-9155/55/11/n03] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
44
|
Bral S, Duchateau M, Versmessen H, Verdries D, Engels B, De Ridder M, Tournel K, Collen C, Everaert H, Schallier D, De Greve J, Storme G. Toxicity report of a phase 1/2 dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer 2010; 116:241-50. [PMID: 19918925 DOI: 10.1002/cncr.24732] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND The objective of the current study was to evaluate the feasibility and toxicity of radiation dose escalation with concurrent chemotherapy using helical tomotherapy (HT) in patients with inoperable, locally advanced, stage III nonsmall cell lung cancer (LANSCLC) (grading determined according to the American Joint Committee on Cancer 6th edition grading system). METHODS This phase 1/2 study was designed to determine the maximum tolerated dose (MTD) of radiotherapy in patients with LANSCLC administered concurrently with docetaxel and cisplatin. Radiotherapy was delivered using HT. A dose per fraction escalation was applied starting at 2 grays (Gy), with an increase of 6% per dose cohort (DC). The Radiation Therapy Oncology Group acute radiation morbidity score was used to monitor pulmonary, esophageal, and cardiac toxicity. RESULTS Dose escalation was performed in 34 patients over 5 DCs to a dose per fraction of 2.48 Gy. No differences were observed in acute toxicity between the different DCs. However, a significant increase in late lung toxicity in DC IV, which received a fraction size of 2.36 Gy, necessitated a halt in further dose escalation with the MTD defined as 2.24 Gy per fraction. The overall incidence of acute grade > or =3 esophageal and pulmonary toxicity was 24% and 3%, respectively (grading determined according to the Radiation Therapy Oncology Group-European Organisation for Research and Treatment of Cancer toxicity scoring system). The overall incidence of late lung toxicity was 21%, but the incidence was an acceptable 13% in DCs I, II, and III. The local response rate was 61% on computed tomography images. CONCLUSIONS The use of HT to 67.2 Gy with concurrent cisplatin/docetaxel was feasible and resulted in acceptable toxicity. A full phase 2 study has been initiated to establish the true local response rate at the MTD of 2.24 Gy per fraction.
Collapse
Affiliation(s)
- Samuel Bral
- Department of Radiation Oncology, Oncology Center, Brussels University Hospital, Brussels, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Palma DA, Verbakel WFAR, Otto K, Senan S. New developments in arc radiation therapy: a review. Cancer Treat Rev 2010; 36:393-9. [PMID: 20181430 DOI: 10.1016/j.ctrv.2010.01.004] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2009] [Revised: 01/14/2010] [Accepted: 01/24/2010] [Indexed: 12/01/2022]
Abstract
Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rationale for arc therapy, descriptions of the modern arc techniques that are currently clinically available, and highlights some distinguishing features of arc therapies, such as dose distributions, treatment times, and imaging capabilities. Arc therapies are exciting examples of progress in radiotherapy through technological innovation, aimed at ultimately improving the therapeutic ratio for patients receiving radiation.
Collapse
Affiliation(s)
- David A Palma
- Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
| | | | | | | |
Collapse
|
46
|
[Total body irradiation: present and future]. Cancer Radiother 2009; 13:428-33. [PMID: 19615929 DOI: 10.1016/j.canrad.2009.04.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2009] [Revised: 04/29/2009] [Accepted: 04/29/2009] [Indexed: 11/21/2022]
Abstract
Total body irradiation (TBI) has an established role as preparative regimen for bone-marrow transplantation in the treatment of hematological malignancies. Many randomized trials demonstrated that the clinical outcomes obtained from the association of TBI and cyclophosphamide are equivalent, or, sometimes, better than those based on chemotherapeutic agents. Despite the therapeutic progress of the last years, and the consequent improvement in the overall survival, this preparative regimen remains always associated with a relatively high rate of acute and late toxicity. In this article, we review the actual indications of TBI in clinical practice, and analyze the technological progress in this domain. We focus on the hypothesis that a selective irradiation of the hematopoietic or lymphoid organs is actually possible with intensity-modulated radiotherapy. Technical limits and preliminary results in terms of acute and late toxicities of intensity-modulated TBI are analyzed. With these new technologies, treatment-related toxicity is not anymore a major limiting factor in the preparative regimens for bone-marrow transplantation, allowing for a larger spectrum of TBI indications, a possible extension to patients older than 50 years, or a dose escalation. Preliminary results warrant, however, further evaluation in clinical trials to better assess the impact of this new approach on disease control and the long-term toxicity.
Collapse
|
47
|
Sterpin E, Salvat F, Olivera G, Vynckier S. Monte Carlo evaluation of the convolution/superposition algorithm of Hi-Art™ tomotherapy in heterogeneous phantoms and clinical cases. Med Phys 2009; 36:1566-75. [DOI: 10.1118/1.3112364] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
48
|
Mc Parland NA. kV-Cone Beam CT as an IGRT Tool in the Treatment of Early Stage Prostate Cancer: A Literature Review. J Med Imaging Radiat Sci 2009; 40:9-14. [PMID: 31051791 DOI: 10.1016/j.jmir.2008.12.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2008] [Revised: 11/30/2008] [Accepted: 12/04/2008] [Indexed: 11/29/2022]
Abstract
Image-guided radiation therapy (IGRT) is an important quality assurance measure that can be used in tandem with conformal radiation therapy treatment. Cone beam computed tomography (CBCT) is a sophisticated IGRT technology that has recently been introduced to the clinical setting. Cone beam equipment includes kilovoltage (kV) CBCT that produces online, high-quality, three-dimensional images of the prostate gland. Interfractional displacements of the prostate can be quantified and adjustments made using kV-CBCT so that daily RT can be accurately delivered. In addition, the volumetric nature of CBCT allows deformations of the prostate gland and surrounding anatomy to be accounted for using adaptive radiation therapy strategies. This article provides an introduction to the main IGRT tools that can be used in parallel with conformal radiation therapy of prostate cancer. A literature review is performed to describe the major IGRT approaches; however, the focus will remain primarily on the technical and clinical applications of kV-CBCT. Important considerations including patient dose, resource implications, and possible changes to the radiation therapist's scope of practice are also discussed.
Collapse
Affiliation(s)
- Neil A Mc Parland
- Radiation Therapy, British Columbia Cancer Agency, Vancouver Center, BC.
| |
Collapse
|
49
|
Quality Control of Portal Imaging with PTW EPID QC PHANTOM. Strahlenther Onkol 2009; 185:56-60. [PMID: 19224148 DOI: 10.1007/s00066-009-1905-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2008] [Accepted: 10/15/2008] [Indexed: 10/21/2022]
Abstract
PURPOSE Quality assurance (QA) and quality control (QC) of different electronic portal imaging devices (EPID) and portal images with the PTW EPID QC PHANTOM. MATERIAL AND METHODS Characteristic properties of images of different file formats were measured on Siemens OptiVue500aSi, Siemens BeamView Plus, Elekta iView, and Varian PortalVision and analyzed with the epidSoft 2.0 program in four radiation therapy centers. The portal images were taken with Kodak X-OMAT V and the Kodak Portal Localisation ReadyPack films and evaluated with the same program. RESULTS The optimal exposition both for EPIDs and portal films of different kind was determined. For double exposition, the 2+1 MU values can be recommended in the case of Siemens OptiVue500aSi Elekta iView and Kodak Portal Localisation ReadyPack films, while for Siemens BeamView Plus, Varian PortalVision and Kodak X-OMAT V film 7+7 MU is recommended. CONCLUSION The PTW EPID QC PHANTOM can be used not only for amorphous silicon EPIDs but also for images taken with a video-based system or by using an ionization chamber matrix or for portal film. For analysis of QC tests, a standardized format (used at the acceptance test) should be applied, as the results are dependent on the file format used.
Collapse
|
50
|
McCutchen KW, Watkins JM, Eberts P, Terwilliger LE, Ashenafi MS, Jenrette JM. Helical tomotherapy for total lymphoid irradiation. ACTA ACUST UNITED AC 2009; 26:622-6. [PMID: 19132495 DOI: 10.1007/s11604-008-0281-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2008] [Accepted: 09/16/2008] [Indexed: 12/01/2022]
Abstract
Total lymphoid irradiation is employed in the preparative regimens for allogeneic bone marrow and solid organ transplantation, solid organ transplant rejection, and chronic graft-versus-host disease. Linear accelerator-based radiotherapy, typically involving opposed anteroposterior and posteroanterior beams, has been commonly used; however, extended source-to-skin patient setup and/or field matching are required, and all organs within the beam coverage receive the entire prescribed dose. Megavoltage helical tomotherapy represents a technological advance in terms of both treatment delivery and patient positioning. The continuously rotating multileaf collimated fan beam allows highly conformal coverage of complex target geometries, in turn allowing avoidance of radiosensitive adjacent organs. In addition, the megavoltage computed tomographic scans allow potentially more accurate, targetbased setup verification. The present case report describes tomotherapy-based total lymphoid irradiation in an adult patient with late-onset cardiac transplant rejection. Treatment planning allowed dose minimization to the spinal cord, kidneys, intestinal compartment, and lungs. The patient tolerated treatment well without acute adverse effects, and he is now in early follow-up.
Collapse
Affiliation(s)
- Kathryn W McCutchen
- Department of Radiation Oncology, Medical University of South Carolina, 169 Ashley Avenue, Charleston, SC 29425, USA
| | | | | | | | | | | |
Collapse
|